The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer
- 13 February 2009
- journal article
- research article
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 119 (3), 551-558
- https://doi.org/10.1007/s10549-009-0333-1
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Validation of 70-gene prognosis signature in node-negative breast cancerBreast Cancer Research and Treatment, 2008
- The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1–3 positive lymph nodes in an independent validation studyBreast Cancer Research and Treatment, 2008
- Clinical Application of the 70-Gene Profile: The MINDACT TrialJournal of Clinical Oncology, 2008
- Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast CancerJNCI Journal of the National Cancer Institute, 2006
- Changes in Gene Expression Associated With Response to Neoadjuvant Chemotherapy in Breast CancerJournal of Clinical Oncology, 2005
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741Journal of Clinical Oncology, 2003
- A Gene-Expression Signature as a Predictor of Survival in Breast CancerThe New England Journal of Medicine, 2002
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002
- pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐upHistopathology, 1991